Human papillomavirus vaccination for adults aged 30 to 45 years in the United States: A cost-effectiveness analysis

BACKGROUND: A nonavalent human papillomavirus (HPV) vaccine has been licensed for use in women and men up to age 45 years in the United States. The cost-effectiveness of HPV vaccination for women and men aged 30 to 45 years in the context of cervical cancer screening practice was evaluated to inform...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Jane J., Simms, Kate T., Killen, James, Smith, Megan A., Burger, Emily A., Sy, Stephen, Regan, Catherine, Canfell, Karen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7951902/
https://www.ncbi.nlm.nih.gov/pubmed/33705382
http://dx.doi.org/10.1371/journal.pmed.1003534

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7951902/
https://www.ncbi.nlm.nih.gov/pubmed/33705382
http://dx.doi.org/10.1371/journal.pmed.1003534

Ejemplares similares